Lipocine (LPCN)
(Real Time Quote from BATS)
$5.52 USD
-0.10 (-1.78%)
Updated May 16, 2024 02:06 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 41 - 60 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
LPCN 1021''s Two Post-CRL Phase 3s Hit Primary Endpoints
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Q1 Reported; 1021s Pivotal, Post-CRL Data in June, Sets up 1Q18 PDUFA
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Dosing Study Readouts Next Month Should Right the Ship Ahead of Pre-Term Birth SPA
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
Dosing Study Enrollment Leaves First Oral Testosterone Approval on Tip of FDA''s Tongue
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Enrollment Complete in Two Post-CRL Studies; Data in June
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Q2 Dosing Studies Could Put 1021 Back in the Saddle
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Q4''16 Reported; Next Up- Oral TRT Ph3s in Q2; Reiterate Buy and $38PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.